|
rs7080536
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A single nucleotide polymorphism (G534E) in HABP2 leads to lower enzymatic activity and is associated with enhanced liver fibrosis in humans.
|
27462075 |
2016 |
|
rs7080536
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The G534E variant of FSAP is a risk locus for HCV-induced liver fibrosis and cirrhosis by determining PDGF-BB-mediated hepatic stellate cell proliferation through a single amino acid substitution in FSAP.
|
19105210 |
2009 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients carrying C282Y had higher mean hepatic iron concentrations (P=0.02), hepatic iron indices (P<=0.0001), and hepatic fibrosis scores (P=0.01).
|
12445428 |
2002 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genetic loci associated with iron metabolism (TF, TMPRSS6, PCSK7, TFR2 and Chr2p14) in recent GWAS and liver fibrosis (PNPLA3) in recent meta-analysis were analyzed for association with either liver cirrhosis or advanced fibrosis in 148 German HFE C282Y homozygotes.
|
24556216 |
2014 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, glucose intolerance may be important risk factor for the development of hepatic fibrosis in subjects with the C282Y/H63D HFE genotype.
|
16584391 |
2006 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A minimum of .66% C282Y homozygotes have liver fibrosis.
|
16797244 |
2006 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Non-invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis.
|
25495562 |
2015 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For C282Y heterozygous patients, the odds ratios for marked inflammatory activity (A2-4) and advanced liver fibrosis or cirrhosis (F2-4) are 4.9 and 4.6, respectively, compared with patients carrying homozygous wild-type alleles.
|
15287851 |
2004 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Those with C282Y mutations had significantly more hepatic fibrosis than those without (p<0.05).
|
10488699 |
1999 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis.
|
17680648 |
2007 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Other recent evidence indicates that the prevalence of HFE gene mutations is increased in chronic viral hepatitis and that patients with chronic hepatitis C harboring especially the C282Y mutation are more likely to suffer from advanced hepatic fibrosis or cirrhosis and to do so at younger ages.
|
12957298 |
2003 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
C282Y or H63D heterozygosity is an independent risk factor for liver fibrosis and cirrhosis in HCV infected individuals.
|
12586300 |
2003 |
|
rs1799945
|
|
|
0.020 |
GeneticVariation |
BEFREE |
C282Y or H63D heterozygosity is an independent risk factor for liver fibrosis and cirrhosis in HCV infected individuals.
|
12586300 |
2003 |
|
rs1799945
|
|
|
0.020 |
GeneticVariation |
BEFREE |
However, glucose intolerance may be important risk factor for the development of hepatic fibrosis in subjects with the C282Y/H63D HFE genotype.
|
16584391 |
2006 |
|
rs1800730
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The HFE S65C mutation may lead to mild to moderate hepatic iron overload but neither clinically manifest haemochromatosis nor iron associated extensive liver fibrosis was encountered in any of the patients carrying this mutation.
|
12377814 |
2002 |
|
rs10433937
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that SERPINA1 Pi*S variant conferred an increased risk of developing liver fibrosis, while SERPINA1 Pi*Z and HSD17B13 rs10433937 were not associated with liver fibrosis or cirrhosis of different aetiology.
|
31517326 |
2019 |
|
rs72613567
|
|
|
0.010 |
GeneticVariation |
BEFREE |
HSD17B13 rs10433937 (in high linkage disequilibrium with rs72613567; r 2 =0.96) also showed no overall association with liver disease, but the GG- genotype was associated with reduced risk of liver fibrosis (aOR 0.37, p=0.03).
|
31517326 |
2019 |
|
rs5496
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This study investigated the association of the genetic markers (SNPs), rs5496, rs281437 and rs12979860 polymorphisms, with viral clearance and the progression of hepatic fibrosis in HCV genotype 4 patients who were treated with pegylated interferon and ribavirin.
|
23137758 |
2013 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In a cross-sectional design, liver stiffness (transient elastography), surrogate markers of liver fibrosis (APRI and FIB-4 scores) and rs12979860 genotypes were analysed in 84 HCV/HIV co-infected patients.
|
21813376 |
2011 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
IL28B rs12979860 (IL28B) non-C/C, advanced liver fibrosis and high HCV RNA were considered as established risk factors for treatment failure.
|
24342953 |
2014 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Multivariate analysis revealed IL28B rs12979860 CC genotype (OR = 3.12; 95% CI, 1.72-5.67; P < 0.001), hepatitis C virus RNA < 400,000 IU/ml (OR = 2.21; 95% CI, 1.22-3.99, P < 0.05), age < 45 years (OR = 2.03; 95% CI, 1.11-3.68; P < 0.05), and liver fibrosis stage 0-1 (OR = 1.64; 95% CI, 1.01-2.65, P < 0.05) were independent factors for SVR.
|
26339796 |
2015 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The IL28B rs12979860 CC genotype is associated with a higher prevalence of cirrhosis in HIV-HCV-coinfected patients than CT/TT genotypes, suggesting that IL28B CC carriers may experience a more rapid progression of HCV-related liver fibrosis, perhaps as result of increased liver inflammation.
|
21592993 |
2011 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This translated into high rates of sustained viral response (SVR) among patients carrying CC(rs12979860) despite the presence of high viral load at baseline (SVR 74%), high age (SVR 79%) or severe liver fibrosis (SVR 83%).
|
21692944 |
2011 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Logistic regression analysis adjusting by [Age], [Sex], [HCV viral genotype], [HCV viral load], [HIV viral load], and [CD4 T cells levels] revealed the IL-28B rs12979860 (CT/TT) genotype as a protective factor against alanine aminotransferase (ALT) levels (>100 IU/L), aspartate aminotransferase (AST) levels (>75 IU/L), and AST-to-platelet ratio index (APRI) score for liver fibrosis (>1.5) [OR, (95% CI), p]: ALT [0.026 (0.001-0.576) 0.021]; AST [0.001 (0.000-0.297) 0.019]; APRI [0.031 (0.002-0.41) 0.008].
|
23030669 |
2013 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the multivariable analysis (odds ratio; 95% confidence interval; P value), the rs12979860 CC genotype was a strong predictor of SVR (3.7; 1.6-8.5; 0.002), independent of HCV genotype 3 (8.0; 3.1-21.0; <0.001), serum HCV-RNA less than 600,000 IU/ml (11.9; 3.8-37.4; <0.001) and lack of advanced liver fibrosis (3.5; 1.4-8.9; 0.009).
|
20389235 |
2010 |